Skip to main content
. 2020 Jan 1;11(1):260–271. doi: 10.7150/jca.35067

Figure 5.

Figure 5

Identification of miR-193b-5p in the serum of breast cancer patients and comparison with those with benign disease and healthy controls (A) Scatterplots of the relative expression levels of miR-193b-5p in the serum from healthy controls, benign tumor patients and breast cancer patients. miR-193b5p expression was calculated and is expressed as the miR-193b-5p/U6 expression ratio. (B) ROC curve analysis comparing breast cancer patients, healthy controls, and benign patients by miR-193b-5p, CEA and CA15-3. Left, ROC analysis comparing breast cancer patients with healthy controls by miR-193b-5p, CEA and CA15-3. Right, ROC analysis comparing breast cancer patients with benign disease patients by miR-193b-5p, CEA and CA15-3. (C) ROC curve analysis to identify breast cancer patients, healthy controls, and benign patients by miR-193b-5p combined with CEA or CA15-3 and CEA combined with CA15-3. Left, ROC analysis comparing breast cancer patients with healthy controls by miR-193b-5p+CEA, miR-193b-5p+CA15-3, and CEA+CA15-3. Right, ROC analysis comparing breast cancer patients with benign disease patients by miR-193b-5p+CEA, miR-193b-5p+CA15-3, and CEA+CA15-3. **P<0.01;***P<0.001. (D) Working model of the miR-193b-5p:CD44v6 regulatory axis in breast cancer.